Glaucoma: A 28-Day, Open-label, multi-site, pilot study evaluating the safety and intraocular lowering effect of delivering Travoprost using a punctal plug delivery system (Evolute®) in subjects with elevated intraocular pressure.
In an open-label study, we are evaluating replacing the use of a daily instilled ocular hypotensive drop with a punctal plug delivery system to deliver an eye pressure-lowering drug to the eye for 28 days.
Patients with a history of open-angle glaucoma or ocular hypertension (high eye pressure without glaucoma damage) who meet all study inclusion/exclusion criteria will be asked to discontinue their current hypotensive medication for six weeks. At the end of six weeks, if a subject still meets all study inclusion/exclusion criteria, a drug-releasing punctal plug will be inserted into each eye.
The study will involve a total of five visits (baseline, week 6, the day after, day 7 and day 28 after being inserted with a punctal plug). Subjects will be compensated for their participation in the study.
Clinical Study Coordinator: Jeanne Molineaux, firstname.lastname@example.org